At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Real-World Evidence Study Evaluating Quality of Life Parameters Following Treatment With Robitussin
In Brief
A Phase 4 clinical trial evaluating Robitussin Maximum Strength Cough and Chest Congestion DM and Robitussin Maximum Strength Nighttime Cough DM for Common Cold and Cough. Completed, enrolled 244 participants across 1 site.
Detailed Summary
The purpose of this Real-World Evidence study is to generate real world data from participants with cough associated with the common cold, evaluating the effects in two arms with commercially available cough syrups on health-related quality of life (QoL). Arm 1 includes one cough syrup (which can be used day or night) and Arm 2 includes the daytime cough syrup and a nighttime cough syrup.
Study Details
Timeline
Interventions
Dextromethorphan Hydrobromide, United States Pharmacopeia (USP) 20 milligram (mg) and Guaifenesin, USP 400 mg
Dextromethorphan Hydrobromide, USP 20 mg and Guaifenesin, USP 400 mg
Dextromethorphan Hydrobromide, USP 30 mg and Doxylamine Succinate, USP 12.5 mg